CN110650741A - 用于治疗结直肠癌的喹啉衍生物 - Google Patents

用于治疗结直肠癌的喹啉衍生物 Download PDF

Info

Publication number
CN110650741A
CN110650741A CN201880033526.6A CN201880033526A CN110650741A CN 110650741 A CN110650741 A CN 110650741A CN 201880033526 A CN201880033526 A CN 201880033526A CN 110650741 A CN110650741 A CN 110650741A
Authority
CN
China
Prior art keywords
colorectal cancer
compound
pharmaceutically acceptable
acceptable salt
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880033526.6A
Other languages
English (en)
Inventor
江海
刘雯雯
于鼎
陈莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN110650741A publication Critical patent/CN110650741A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种用于治疗结直肠癌的喹啉衍生物，具体涉及1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺能够有效治疗化疗药物和/或靶向药物治疗失败的结直肠癌，能够稳定或者缓解化疗药物和/或靶向药物治疗失败的结直肠癌患者病情。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201880033526.6A 2017-05-26 2018-05-24 用于治疗结直肠癌的喹啉衍生物 Pending CN110650741A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710382549 2017-05-26
CN2017103825495 2017-05-26
PCT/CN2018/088114 WO2018214925A1 (zh) 2017-05-26 2018-05-24 用于治疗结直肠癌的喹啉衍生物

Publications (1)

Publication Number Publication Date
CN110650741A true CN110650741A (zh) 2020-01-03

Family

ID=64395293

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033526.6A Pending CN110650741A (zh) 2017-05-26 2018-05-24 用于治疗结直肠癌的喹啉衍生物

Country Status (2)

Country Link
CN (1) CN110650741A (zh)
WO (1) WO2018214925A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532189A (ja) * 2019-05-10 2022-07-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 軟部肉腫の併用療法用キノリン誘導体
CN112043702A (zh) * 2019-06-05 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗结直肠癌的喹啉类化合物
CN112294814A (zh) * 2019-07-31 2021-02-02 正大天晴药业集团股份有限公司 用于治疗胶质母细胞瘤的喹啉衍生物
CN112336726A (zh) * 2019-08-09 2021-02-09 正大天晴药业集团股份有限公司 治疗结直肠癌的联用药物组合物
EP4091613A4 (en) * 2020-01-19 2024-02-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. QUINOLINE DERIVATIVE FOR TREATING RHEUMATOID ARTHRITIS
CN112358469A (zh) * 2020-03-18 2021-02-12 北京康辰药业股份有限公司 血管生成抑制剂、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
WO2015185013A1 (zh) * 2014-06-06 2015-12-10 正大天晴药业集团股份有限公司 包含喹啉衍生物或其盐的药物组合物及其制备方法
WO2016179123A1 (en) * 2015-05-04 2016-11-10 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
WO2015185013A1 (zh) * 2014-06-06 2015-12-10 正大天晴药业集团股份有限公司 包含喹啉衍生物或其盐的药物组合物及其制备方法
WO2016179123A1 (en) * 2015-05-04 2016-11-10 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONGKUN SUN等: "Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 *

Also Published As

Publication number Publication date
WO2018214925A1 (zh) 2018-11-29

Similar Documents

Publication Publication Date Title
US10888559B2 (en) Quinoline derivatives for non-small cell lung cancer
CN110650741A (zh) 用于治疗结直肠癌的喹啉衍生物
CN109069500B (zh) 一种用于治疗胃癌的喹啉衍生物
CN114831988A (zh) 治疗非小细胞肺癌的喹啉衍生物
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
KR20220003560A (ko) 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
CN112638385B (zh) 用于治疗脑肿瘤的喹啉衍生物
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN111757736B (zh) 治疗鼻咽癌的喹啉衍生物
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN115484955A (zh) 用于治疗met基因异常疾病的氨基吡啶衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200103

WD01 Invention patent application deemed withdrawn after publication